Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors

J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e591-e593. doi: 10.1111/jdv.17321. Epub 2021 May 13.

Authors

E Povilaityte¹, F F Gellrich¹, S Beissert¹, S Abraham¹, F Meier^{1

2}, C Günther¹

Affiliations

¹ Department of Dermatology, Technische Universität Dresden, Dresden, Germany.
² Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases, Dresden, Germany.

PMID: 33914970
DOI: 10.1111/jdv.17321

No abstract available

Publication types

Letter

MeSH terms

Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use
Humans
Immune Checkpoint Inhibitors
Pemphigoid, Bullous* / chemically induced
Pemphigoid, Bullous* / drug therapy

Substances

Dipeptidyl-Peptidase IV Inhibitors
Immune Checkpoint Inhibitors